TipRanks
Advertisement
Advertisement

IL:CANF Stock Latest News

Can-Fite Buy Rating Reaffirmed as Clinical Momentum Builds and $8 Price Target Remains Unchanged
RatingsCan-Fite Buy Rating Reaffirmed as Clinical Momentum Builds and $8 Price Target Remains Unchanged
3d ago
CANF
Can-Fite reports longer-than-anticipated survival observed in Namodenoson study
PremiumThe Fly
Can-Fite reports longer-than-anticipated survival observed in Namodenoson study
30d ago
CANF
Can-Fite BioPharma files $100M mixed securities shelf
PremiumThe Fly
Can-Fite BioPharma files $100M mixed securities shelf
1M ago
CANF
Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu
PremiumThe Fly
Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu
2M ago
CANF
Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
PremiumThe Fly
Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
3M ago
CANF
Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial
PremiumThe FlyCan-Fite BioPharma enrolls 247 patients in Piclidenoson trial
3M ago
CANF
Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright
Premium
The Fly
Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright
3M ago
CANF
Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint
Premium
The Fly
Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint
3M ago
CANF
Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists
PremiumThe Fly
Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists
3M ago
CANF
Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
PremiumThe Fly
Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
5M ago
CANF
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
PremiumThe Fly
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
5M ago
CANF
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
PremiumThe Fly
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
6M ago
CANF
Can-Fite BioPharma completes enrollment in Piclidenoson study
PremiumThe FlyCan-Fite BioPharma completes enrollment in Piclidenoson study
6M ago
CANF
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
Premium
The Fly
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
7M ago
CANF
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
Premium
The Fly
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
7M ago
CANF
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
PremiumThe Fly
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
8M ago
CANF
Can-Fite BioPharma receives Canadian patent allowance for namodenoson
PremiumThe Fly
Can-Fite BioPharma receives Canadian patent allowance for namodenoson
8M ago
CANF
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
PremiumThe Fly
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
8M ago
CANF
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
PremiumThe Fly
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
8M ago
CANF
Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
PremiumThe FlyCan-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
9M ago
CANF
Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change
Premium
The Fly
Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change
9M ago
CANF
Can-Fite BioPharma provides clinical, financial update
Premium
The Fly
Can-Fite BioPharma provides clinical, financial update
10M ago
CANF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >